Oligomerix Inc.
NY
- UEI
- MHB5HVJVAK87
- CAGE
- 4PQQ8
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1300 Morris Park Ave, Bronx, NY 10461, USA
- Website
- oligomerix.com
- Founded
- 2006
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A 13-week oral gavage toxicity study of OLX-07010 in beagle dogs followed by a 4-week recovery period - project… | National Institute on Aging | $2,491,509 | |
| A 26-week RAT toxicity study and efficacy and biomarker studies in TAU-APP alzheimer's mouse model to support a phase 1B… | National Institute on Aging | $3,617,899 | |
| First in human study of a TAU self-association small molecule inhibitor in healthy volunteers - project summary this… | National Institute on Aging | $14,519,230 | |
| GMP production of a TAU oligomer inhibitor to enable clinical development for adrd | National Institute on Aging | $8,171,769 | |
| Scale-up and synthesis of a TAU oligomer inhibitor to initiate IND enabling studies for ad and adrd | National Institute on Aging | $2,499,352 |
About Oligomerix Inc.
Oligomerix Inc. is a biotechnology company located in West Harrison, New York, focused on developing innovative pharmaceutical interventions for neurodegenerative diseases, specifically Alzheimer's disease. Registered in SAM.gov since 2007, the company operates as a for-profit corporate entity specializing in the research and development of small molecule drugs targeting tau protein aggregation. The company's primary research focus is on creating disease-modifying treatments for Alzheimer's and related tauopathies, with a strategic approach to developing oral, economically viable therapeutic interventions.
Through federal grant awards from the National Institute on Aging, Oligomerix Inc. has been conducting extensive preclinical and clinical research on its lead compound OLX-07010, a small molecule drug designed to inhibit tau self-association. The company has received multiple project grants totaling nearly $500,000 to support various stages of drug development, including a 26-week rat toxicity study, a 13-week dog toxicity study, and preparations for first-in-human Phase 1 clinical trials. These grants have supported critical research activities such as efficacy and biomarker studies in Alzheimer's mouse models, pharmacological screening, drug manufacturing, and toxicology assessments. The research aims to develop a potentially transformative treatment for Alzheimer's disease, with a focus on creating a drug that is oral, self-administered, and capable of addressing the growing global challenge of neurodegenerative disorders.
Quick answers
What is Oligomerix Inc.'s UEI?
Oligomerix Inc.'s Unique Entity ID (UEI) in SAM.gov is MHB5HVJVAK87.
What is Oligomerix Inc.'s CAGE code?
Oligomerix Inc.'s CAGE code is 4PQQ8.
Where is Oligomerix Inc. located?
Oligomerix Inc.'s physical address in SAM.gov is 1300 Morris Park Ave, Bronx, NY 10461, USA.
Is Oligomerix Inc. registered in SAM.gov?
Yes. Oligomerix Inc.'s SAM.gov registration is active through January 20, 2027.
What is Oligomerix Inc.'s most recent federal award?
Oligomerix Inc.'s most recent federal grant award is A 13-week oral gavage toxicity study of OLX-07010 in beagle dogs followed by a 4-week recovery period - project… (R44AG091987), from National Institute on Aging, on August 20, 2025.
On GovTribe
See Oligomerix Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors